Camlin Fine Sciences DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.01×−0.70×−3.23×1.06×0.50×
−6.52×−0.94×0.34×21.16×0.56×
0.6%2.1%8.7%−0.3%8.5%
0.79×0.79×0.84×0.80×0.99×
2.32×2.32×2.31×2.28×2.50×
0.1%2.5%−18.4%−11.8%5.9%
2.8%2.8%−15.7%−11.0%7.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAMLINFINE₹82.32

Camlin Fine Sciences Limited

· Chemicals
₹ CrorePeersCLEANDEEPAKNTRBAYERCROPTIRUMALCHMATULSHKPAUSHAKLTDANURASMcap ₹1,581 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.501.06-3.23-0.70-0.01
Interest Burden (Pretax/EBIT) ×0.5621.160.34-0.94-6.52
EBIT Margin %8.49-0.298.662.090.56
Asset Turnover ×0.990.800.840.790.79
Financial Leverage (Assets/Equity) ×2.502.282.312.322.32
ROE (5-step product, year-end total equity) %5.86-11.85-18.442.510.06
ROE (owners' profit / average owners' equity) %7.38-11.02-15.742.842.84
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.